Premium
Aminoglycoside dosing in diabetes [Note 1. At the time of writing, Sheri Axworthy was a ...]
Author(s) -
S. Axworthy,
Don Gardner
Publication year - 2000
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1046/j.1365-2710.2000.00267.x
Subject(s) - dosing , medicine , diabetes mellitus , aminoglycoside , toxicity , renal function , population , intensive care medicine , pharmacology , antibiotics , endocrinology , biology , environmental health , microbiology and biotechnology
Studies have evaluated the comparative efficacy, toxicity and costs associated with extended‐interval vs. standard multiple daily dosing of aminoglycosides. In this case, an elderly man with diabetes and good renal function at baseline was switched from standard to extended‐interval dosing. During the course of therapy there was evidence of decreased renal function. Pertinent literature was searched for, uncovered and critically evaluated to determine if and what evidence supports using extended dosing of aminoglycosides in this population. No data were found specifically evaluating the different dosing strategies in diabetic patients. However, there were many trials and several meta‐analysis located that compared the two dosing strategies, most suggesting at least a cost advantage and possibly less toxicity with extended‐interval dosing. Further information is needed to determine whether there is a differential risk for toxicity between these dosing regimens in patient with diabetes.